This study was designed in an attempt to elucidate a mechanism of somatostatin inhibition of glucose-induced Ca
2+ uptake by rat pancreatic islets.
Rat pancreatic islets were perifused with Krebs-Ringer bicarbonate (KRB) buffer containing16.7mM of glucose with somatostatin (2μg/m
l) or/and diltiazem HCl (2×10
-5M). Somatostatin inhibited preferentially the early phase of glucose-induced insulin release, whereas diltiazem HC1 inhibited the late one. And the concomitant presence of the submaximal concentration of somatostatin (2μg/m
l) and diltiazem H1l (2×10
-5M) provided the completely additive inhibition of glucose-induced insulin release.
Rat pancreatic islets were incubated with KRB buffer supplemented with 16.7mM of glucose and
45CaCl
2 (10μCi/m
l) for 5-60 min and the biphasic
45Ca uptake by pancreatic islets was obtained. Somatostatin (500ng/m
l-4μg/m
l) gave the suppressive effect on the early phase of glucose-induced
45Ca uptake, but the higher concentration (2μg/m
l) of somatostatin did not impair the late phase of
45Ca uptake by pancreatic islets.
On the other hand, diltiazem HCl did suppress the late phase of glucose-induced
45Ca uptake dose-dependently, but did not suppress the early phase (2×10
-5M).
These data indicate that somatostatin suppresses the early phase of glucoseinduced Ca
2+uptake preferentially to the late one and has a different action mechanism from Ca antagonist on glucose-induced insulin release.
View full abstract